Health officials in New York are investigating vitamin E's connection to a string of vaping illnesses in the state; civil rights groups are suing the Trump administration over its decision to deport immigrants with life-threatening illnesses; an oncologist from MD Anderson Cancer Center met with President Trump about a potential nomination for FDA commissioner.
New York health officials are investigating the role of vitamin E acetate in a string of illnesses related to vaping, reported The New York Times. According to the state's Department of Health, there were “very high levels” of the compound identified in 13 samples from 8 of 34 patients in the state who have gotten sick. However, the case is not closed on what’s causing these illnesses, particularly since the compound hasn’t been confirmed as a factor in the majority of the cases. A spokesman for the FDA said that more information is needed to better understand if there’s a link between any specific substances and the illnesses.
Days after the Trump administration announced that it would reconsider its decision to deport immigrants with life-threatening illnesses, civil rights groups are suing the administration over the decision. The American Civil Liberties Union of Massachusetts and Lawyers for Civil Rights filed a lawsuit in Boston federal court challenging the decision to end the deferred action program as of August 7, according to The Associated Press. The groups argue that the decision was made without the advance public notice and justification required by law before changing a significant federal government regulation.
With the Trump administration looking to nail down a permanent FDA commissioner by November 1, STAT News has reported that Texas oncologist Stephen Hahn, MD, FASTRO, chief medical executive at MD Anderson Cancer Center, met with the president on Wednesday about a possible nomination. Unlike many past commissioners, Hahn has no Washington experience. Acting FDA Commissioner Ned Sharpless, MD, is also in the running, according to experts. Four former FDA commissioners have come out in support of Sharpless.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More